Pyxis Oncology Inc
NASDAQ:PYXS

Watchlist Manager
Pyxis Oncology Inc Logo
Pyxis Oncology Inc
NASDAQ:PYXS
Watchlist
Price: 1.62 USD 0.62% Market Closed
Market Cap: $100.9m

Operating Margin

-3 776.1%
Current
Declining
by 2 684.9%
vs 3-y average of -1 091.2%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-3 776.1%
=
Operating Income
$-106.5m
/
Revenue
$2.8m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-3 776.1%
=
Operating Income
$-106.5m
/
Revenue
$2.8m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Pyxis Oncology Inc
NASDAQ:PYXS
100.1m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
394.7B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
175B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.2B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.6B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.1B AUD
Loading...
NL
argenx SE
XBRU:ARGX
44.8B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.5B USD
Loading...

Market Distribution

Lower than 95% of companies in the United States of America
Percentile
5th
Based on 14 112 companies
5th percentile
-3 776.1%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Pyxis Oncology Inc
Glance View

Market Cap
100.9m USD
Industry
Biotechnology

Pyxis Oncology, Inc. engages in the development of antibody therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 56 full-time employees. The company went IPO on 2021-10-08. The firm has developed a portfolio of antibody drug conjugate (ADC), immuno-oncology (IO), product candidates, and monoclonal antibody (mAb), preclinical discovery programs that are developing as monotherapies and in combination with other therapies. Its pipeline includes PYX-106, PYX-102, PYX-201, PYX-202 and PYX-203. Its PYX-106 is an investigational, fully human IgG1 isotype Siglec-15 targeting antibody that is designed to block Siglec-15-mediated suppression of T-cell proliferation and function. PYX-102 is an investigational immune-therapeutic consisting of a ligand-blocking antibody which rescues KLRG1-mediated suppression of human CD8+ T cells. PYX-201 is an investigational ADC consisting of an immunoglobulin G1 (IgG1), anti-fibronectin Extradomain-B (EDB), mAb site-specifically conjugated to auristatin via a cathepsin B-cleavable linker.

PYXS Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-3 776.1%
=
Operating Income
$-106.5m
/
Revenue
$2.8m
What is Pyxis Oncology Inc's current Operating Margin?

The current Operating Margin for Pyxis Oncology Inc is -3 776.1%, which is below its 3-year median of -1 091.2%.

How has Operating Margin changed over time?

Over the last 1 years, Pyxis Oncology Inc’s Operating Margin has decreased from -414% to -3 776.1%. During this period, it reached a low of -3 776.1% on Jul 30, 2025 and a high of -414% on Mar 31, 2024.

Back to Top